FINALLY, we have very encouraging news on the hydroxychloroquine (HCQ) front!
SIX positive clinical studies were released at the beginning of July:
- three from the United States (one from Michigan at Henry Ford Hospital, and two from New York state, including the one by Dr. Vladimir Zelenko),
- three from other countries (Portugal, India, and Brazil)
The bottom line from all six: HCQ given early in COVID-19, alone or with zinc and azithromycin, reduces hospitalizations and deaths, with no serious heart or other adverse events in the short 5-7 day course of treatment for COVID-19.
Most media ignored these six positive studies, continuing to focus on fear-mongering about HCQ “dangers” from now discredited, poorly designed and seriously flawed reports from use in critically ill hospitalized patients.
Then in a stunning development, Henry Ford Health System (Detroit MI) team of physicians, researchers and ethicists in early July filed an urgent application with FDA Commissioner Dr. Hahn applying for FDA to issue a new Emergency Use Authorization (EUA) and approval of HCQ for COVID-19 early, outpatient use. The Henry Ford clinical trial of HCQ early in hospitalized COVID patients showed a 50% reduction in deaths. This open letter supports this FDA EUA Request and is signed by clinicians, medical researchers, statisticians, and ethicists…